Represented by gefitinib and erlotinib, the first‐generation EGFR inhibitors are noncovalent ATP‐competitive inhibitors of WT EGFR and have shown good efficacy in NSCLC patients with the EGFR L858R/19del mutation.218, 219, 220. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.